|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45.3 USD | +1.98% |
|
-1.93% | -24.71% |
| Apr. 23 | Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission | MT |
| Apr. 22 | Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer | MT |
March 15 (Reuters) - Advisers to the U.S. Food and Drug Administration on Friday unanimously voted in favor of allowing the use of Johnson & Johnson's cell therapy as an earlier treatment for a type of blood cancer.
All eleven voting members of the panel agreed that benefits of J&J's Carvykti outweighed the risks of the therapy when given as an earlier treatment. (Reporting by Bhanvi Satija and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 146.1 USD | -0.46% | -1.20% | 352B | ||
| 45.3 USD | +1.98% | -1.93% | 8.24B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| -24.71% | 8.24B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
LEGEND BIOTECH CORPORATION 
